Home > Journals > Minerva Endocrinologica > Past Issues > Minerva Endocrinologica 2008 September;33(3) > Minerva Endocrinologica 2008 September;33(3):159-67



To subscribe
Submit an article
Recommend to your librarian





Minerva Endocrinologica 2008 September;33(3):159-67


language: English, Italian

Testosterone therapy improves the clinical response to conventional treatment for male patients with metabolic syndrome associated to late onset hypogonadism

La Vignera S., Calogero A. E., D’Agata R., Di Mauro M., Tumino S., Condorelli R., Lanzafame F., Finocchiaro C., Giammusso B., Vicari E.

Endocrinology, Andrology and Internal Medicine Unit, Department of Biomedic Scieces, University of Catania, Garibaldi Hospital, Catania, Italy


Aim. Recently, the clinic characterization of the gonadic male function has been put in tight correlation on the pathogenetic level with the main variables forming the condition of metabolic syndrome (MS); probably the serum testosterone (T) concentration in males is to be considered as an additional parameter completely related to the traditional clinical-metabolic findings. Currently the matter of the substitutive hormonal therapy with androgens is apparently influenced by some important unresolved aspects: 1) who really benefits from the T therapy? 2) are the actual dosage methods of T reliable? 3) which vascular and metabolic targets are to be monitored during the T therapy?
Methods. In an analytical longitudinal study, carried out 12 months long on 60 men (average age 58 years, range 54-63 years) affected by metabolic syndrome (MS) and combined hypogonadism late onset (LOH), authors have evaluated the clinical response (androgenic asset, non-invasive hospital monitoring of the arterial pressure, lipidic asset study, body composition and the biologic resistance to the insulinic action) after conventional medical therapy (insulin-sensibilizing and anti-hypertensive) and after substitutive hormonal therapy with testosterone (T) by transdermic way. A group of five patients with MS and LOH, not treated, was used as group of control.
Results. The group of patients treated with T showed a profile of clinical response better than the group of controls.
Conclusion. In conclusion, the seric determination of T is useful to better characterize the dismetabolic patient at the moment of the first level active medical therapy planning on the controls of the main risk factors constituting MS, expressing a potential role of conditioning.

top of page